Le Lézard
Classified in: Oil industry, Environment, Science and technology, Business
Subject: CON

Call for tenders for the purchase of wind power integration service


MONTREAL, Feb. 27, 2020 /CNW Telbec/ - Today Hydro-Québec Distribution issued a call for tenders for the purchase of wind power integration service for all wind farms under contract. Given the intermittent nature of wind power, such a service is required in order to balance wind power generation on Hydro-Québec's transmission grid, in real-time.

The wind power integration service required in this call for tenders is comprised of a balancing service to guarantee wind energy deliveries as well as additional firm capacity during winter months, from December 1 to March 31.

The contracts will cover a five-year period from the commencement date of deliveries. Balancing services must be supplied by September 1, 2020. This call for tenders is open to all interested bidders. The wind power integration service can be rendered by more than one supplier and must come from an existing generation facility located in Québec.

The deadline for submitting bids is April 24, 2020. The call for tenders document, the registration form for the pre-bid conference, the call for tenders registration form and the bid form are available on Hydro-Québec Distribution's Web site: http://www.hydroquebec.com/distribution/en/marchequebecois/index.html

Hydro-Québec Distribution has retained the services of Raymond Chabot Grant Thornton to assist in the tendering process, analyze received bids and act as its official representative. 

SOURCE Hydro-Québec


These press releases may also interest you

at 07:10
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent...

at 07:10
IMV Inc. , a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company's business and clinical operations amid...

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....

at 07:05
Generation Bio and Vir Biotechnology today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's current or future human monoclonal...



News published on 27 february 2020 at 09:02 and distributed by: